Drug discovery specialists at Ligand take their antibody biz public via SPAC, aiming to build $850M company

Amber Tong

When Ligand Pharmaceuticals unveiled plans to spin off its antibody discovery unit, OmniAb, last November, the board of directors had yet to approve a specific …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Drug discovery specialists at Ligand take their antibody biz public via SPAC, aiming to build $850M company

Amber Tong

Sign up to read this article for free.

Danish biotech Gubra touts early weight loss data in hot amylin field

After stock slides, Amgen addresses bone density talk on obesity drug

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

J&J takes 340B fight with federal government to court

'Expertise is a real thing': FDA commissioner warns of political risk to agency

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Drug dis­cov­ery spe­cial­ists at Lig­and take their an­ti­body biz pub­lic via SPAC, aim­ing to build $850M com­pa­ny

Amber Tong

Sign up to read this article for free.

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Drug discovery specialists at Ligand take their antibody biz public via SPAC, aiming to build $850M company

Danish biotech Gubra touts early weight loss data in hot amylin field

After stock slides, Amgen addresses bone density talk on obesity drug

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

J&J takes 340B fight with federal government to court

'Expertise is a real thing': FDA commissioner warns of political risk to agency

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?